Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Suspended  
  • Page 1 ·  Next »

NCT ID: NCT02564549 Suspended - Prostate Cancer Clinical Trials

MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca

Start date: October 5, 2015
Phase: N/A
Study type: Interventional

Phase II non-inferiority randomized trial of annual systematic biopsies versus mpMRI and targeted biopsies for men with low risk prostate cancer on active surveillance with any volume Gleason's Score 6, but no prior MRI imaging of the prostate.

NCT ID: NCT02091661 Suspended - Prostate Cancer Clinical Trials

Radical Retropubic Prostatectomy Versus Conventional External Beam Radiotherapy for Clinically Localized Prostate Cancer

Start date: January 1997
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of the two most established primary treatments for patients with clinically localized prostate cancer: radical retropubic prostatectomy, and external-beam radiotherapy. The primary aim is assessing biochemical disease-free survival, overall survival, and prostate cancer-specific survival. As secondary objectives quality of Life impact of treatments' side effects will be also assessed.

NCT ID: NCT02061345 Suspended - Prostate Cancer Clinical Trials

PET Imaging in MCI Following ADT for PCa

Start date: April 2014
Phase: N/A
Study type: Observational

Mild cognitive impairment (MCI) with ageing is thought in part to be related to reduced serum sex hormones which is well-recognized, especially in females, but poorly understood. International studies assessing hormone replacement therapy (HRT) to prevent/reduce MCI are ongoing. MCI leads to morbidity, reduced quality of life and substantial healthcare costs. The commonest therapeutically induced reduction in sex hormone level in men is treatment of prostate cancer (PCa). PCa is androgen dependent and androgen deprivation therapy (ADT) suppressing testosterone to castrate levels is key therapy for advanced disease. About one million men worldwide have received ADT for PCa, mostly using luteinising hormone releasing hormone agonists (LHRHa) although oral oestrogens were used in the past; eventually perhaps 4% of Caucasians may be castrated. MCI as a side effect of castration in men remains poorly researched. This study aims to demonstrate that pathological changes occur in the brains of a significant proportion of prostate cancer patients subjected to ADT that correlate with MCI symptoms. Highlighting the pathological changes of MCI should improve understanding and interventions for slowing/preventing MCI in PCa survivors. Brain scans employing positron emission tomography (PET) imaging technique will be used to detect the presence of pathological changes in the brain that relate to ADT induced MCI. MCI will be assessed by neuropsychological assessments (standard paper-based questionnaires and online) and its neural basis will be investigated using magnetic resonance imaging (MRI).

NCT ID: NCT02053311 Suspended - Prostate Cancer Clinical Trials

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Start date: June 2014
Phase: Phase 3
Study type: Interventional

The main object of this multicenter, randomized, double-blind, placebo-controlled phase III trial is to assess impact of maintenance of orteronel on disease progression and hence on quality of life of patients with metastatic castration resistant prostate cancer pretreated with novel hormonal agents who have non-progressive disease after chemotherapy with a taxane.

NCT ID: NCT01478828 Suspended - Prostate Cancer Clinical Trials

Pre-Prostatectomy Lovastatin on Prostate Cancer

Start date: March 2012
Phase: N/A
Study type: Interventional

To determine the dose of continuous daily oral lovastatin needed to achieve MYC [v-myc myelocytomatosis viral oncogene homolog (avian)] down-regulation in prostatectomy specimens in intermediate-/high-risk localized prostate cancer patients.

NCT ID: NCT00999960 Suspended - Prostate Cancer Clinical Trials

Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator

PERLE
Start date: February 2010
Phase: N/A
Study type: Interventional

To evaluate the clinical impact of an online video simulator during the learning period of laparoscopic radical prostatectomy.

NCT ID: NCT00909558 Suspended - Breast Cancer Clinical Trials

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

Start date: May 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung cancer, pancreatic cancer, colon cancer or prostate cancer.

NCT ID: NCT00744549 Suspended - Prostate Cancer Clinical Trials

Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance

Start date: May 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether antioxidants (vitamin E, selenium and lycopene)can change(reduce)prostate tumor size or blood flow to the prostate as determined by MRI imaging among men on Active Surveillance.

NCT ID: NCT00664196 Suspended - Prostate Cancer Clinical Trials

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

Start date: April 2008
Phase: Phase 1
Study type: Interventional

This study tests the safety and tolerability of autologous anti-PSMA gene-modified T cells (designer T cells) in hormone refractory prostate cancer.

NCT ID: NCT00407875 Suspended - Prostate Cancer Clinical Trials

Intensity Modulated Versus Interstitial - Radiation Therapy

Start date: March 2007
Phase: Phase 2
Study type: Interventional

Purpose: The purpose of this trial is to compare two different treatment options for patients with low risk and low-tier intermediate risk prostate cancer. The two treatment arms being compared in this study are: (control arm) permanent interstitial prostate brachytherapy (PIPB) VERSUS (experimental arm) intensity modulated external beam radiation therapy (IMRT). Hypothesis: The acute and late toxicities experienced by patients in the experimental arm (IMRT) are not significantly worse then the toxicities experienced by patients in the control arm (PIPB).